Micro Needle. Macro Benefits.
Improved immunogenicity and
dose sparing
Our extensive clinical trials have shown improved immunogenicity and dose sparing over both intramuscular 1-7, 10 and subcutaneous8 delivery, as well as over intradermal delivery using the Mantoux technique3
Practically painless injection
When it comes to microneedles, less is more.
As the smallest hollow needle in the market (just 0.6mm long), MicronJetTM microneedle allows for a practically painless intradermal injection8,9
Consistent intradermal delivery
Due to its unique design the MicronJetTM microneedle is one of the shallowest and most consistent forms of intradermal delivery4-9
Extensive Clinical Experience
Numerous Trials
In addition to global commercial sales, NanoPass’s MicronJetTM Technology has been used to administer over 27,000 injections to approximately 5,700 patients in more than 55 completed and ongoing clinical trials
Validated Benefits
MicronJetTM has demonstrated a superior immune response with full dose2,3,5, 8,10 and equivalence or a trend for superiority with lower doses (4-40%)1-8,10
Patented Technology
Intradermal delivery
Intradermal vaccine delivery has been repeatedly shown to allow significant dose sparing when compared to conventional administration methods**
Robust design
NanoPass’s MicronJetTM microneedles are based on MEMS (Micro electro mechanical Systems) technology and are made of pure silicon crystal
Video Gallery
How to perform a MicronJet600 injection
The beauty of a MicronJet600 injection into the air
About NanoPass
NanoPass Technologies Ltd. is a pioneer in the development and commercialization of nearly painless intradermal delivery solutions for vaccines and drugs. Its flagship product, the 0.6mm MicronJet600 microneedle, is the first and only true (<1mm) microneedle to receive FDA clearance as an intradermal delivery device for substances approved for delivery below the surface of the skin and is also CE certified.
Nanopass is ISO 13485 certified.
*See references
**Darin Zehrung et al. intradermal delivery for vaccine dose sparing: overview of current issues. Vaccine 31 (2013) 3392-3395